Medtronic backs antisense-coated stent with early data
This article was originally published in Clinica
Executive Summary
Medtronic's stent coated with AVI BioPharma's NeuGene antisense compound, Resten-NG, has produced promising results in a preclinical study. Data showed that the drug-coated device can not only significantly reduce coronary restenosis, but it may also allow arteries to heal faster than other compounds currently being assessed on stents, claimed AVI, of Portland, Oregon.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.